GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Brokerages

Key Points

• GSK PLC has received an average recommendation of "Reduce" from eight research firms, with one sell rating and seven hold ratings.
• Shares of GSK opened at $43.36 and have a target price of $37.3750 as per brokerages, reflecting a significant drop potential from current levels.
• The company recently announced a quarterly dividend of $0.4206 per share, resulting in an annualized yield of 3.9%, despite a high payout ratio of 77.78%.

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) has earned an average rating of "Reduce" from the eight research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $37.3750.

Several analysts have issued reports on GSK shares. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Weiss Ratings reissued a "hold (c)" rating on shares of GSK in a research note on Wednesday.

GSK Price Performance

Shares of GSK opened at $43.36 on Thursday. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.59. The company has a market capitalization of $88.21 billion, a P/E ratio of 20.07, a P/E/G ratio of 1.96 and a beta of 0.53. The business's 50-day moving average is $40.08 and its two-hundred day moving average is $38.78. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company's revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Research analysts predict that GSK will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 3.9%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio (DPR) is 77.78%.

Institutional Trading of GSK

Several institutional investors have recently added to or reduced their stakes in the stock. Twin Peaks Wealth Advisors LLC purchased a new position in shares of GSK during the second quarter worth $25,000. HHM Wealth Advisors LLC boosted its holdings in GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after acquiring an additional 460 shares during the period. Costello Asset Management INC purchased a new position in GSK during the 1st quarter valued at about $31,000. SOA Wealth Advisors LLC. grew its position in GSK by 252.1% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company's stock valued at $32,000 after acquiring an additional 605 shares in the last quarter. Finally, Richardson Financial Services Inc. increased its stake in GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after purchasing an additional 472 shares during the period. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.